Capital Increase in Genmab as a Result of Employee Warrant

0
77


Company Announcement

COPENHAGEN, Denmark; September 27, 2022 Genmab A/S (Nasdaq: GMAB) will enhance its share capital by 18,406 shares as a consequence of the train of worker warrants.

The enhance is effected with none preemption rights for the prevailing shareholders of the corporate or others. The shares are subscribed in money on the following value per share of nominally DKK 1:

133 shares at DKK 815.50,
3,874 shares at DKK 939.50,
367 shares at DKK 962.00,
8,949 shares at DKK 1,025.00,
878 shares at DKK 1,032.00,
50 shares at DKK 1,050.00,
2,990 shares at DKK 1,145.00,
200 shares at DKK 1,161.00,
562 shares at DKK 1,210.00,
158 shares at DKK 1,233.00,
33 shares at DKK 1,402.00,
72 shares at DKK 1,424.00, and
140 shares at DKK 1,432.00.

Proceeds to the corporate are roughly DKK 19.1 million. The enhance corresponds to roughly 0.03% of the corporate’s share capital.

The new shares are extraordinary shares with none particular rights and are freely transferable negotiable devices. The new shares give rights to dividends and different rights in relation to the corporate as of subscription. The new shares will likely be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital enhance is anticipated to be finalized shortly.

Pursuant to part 32 of the Danish Capital Markets Act No. 2014 of November 1, 2021, it’s hereby introduced, that the overall nominal worth of Genmab A/S’ share capital after the capital enhance is DKK 65,829,282 which is made up of 65,829,282 shares of a nominal worth of DKK 1 every, similar to 65,829,282 votes. 

See also  Allergy Treatment Market | North America is Anticipated to Record the Fastest Growth in Upcoming Years

About Genmab
Genmab is a global biotechnology firm with a core objective to enhance the lives of individuals with most cancers. For greater than 20 years, Genmab’s imaginative and prescient to remodel most cancers therapy has pushed its passionate, revolutionary and collaborative groups to invent next-generation antibody know-how platforms and leverage translational analysis and knowledge sciences, fueling a number of differentiated most cancers remedies that make an impression on individuals’s lives. To develop and ship novel therapies to sufferers, Genmab has fashioned 20+ strategic partnerships with biotechnology and pharmaceutical firms. Genmab’s proprietary pipeline contains bispecific T-cell engagers, next-generation immune checkpoint modulators, effector perform enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with places in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For extra data, please go to Genmab.com and comply with us on Twitter.com/Genmab.

Contact:        
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement comprises ahead trying statements. The phrases “believe”, “expect”, “anticipate”, “intend” and “plan” and comparable expressions determine ahead trying statements. Actual outcomes or efficiency could differ materially from any future outcomes or efficiency expressed or implied by such statements. The necessary components that would trigger our precise outcomes or efficiency to vary materially embrace, amongst others, dangers related to pre-clinical and medical growth of merchandise, uncertainties associated to the end result and conduct of medical trials together with unexpected issues of safety, uncertainties associated to product manufacturing, the shortage of market acceptance of our merchandise, our incapability to handle development, the aggressive atmosphere in relation to our business space and markets, our incapability to draw and retain suitably certified personnel, the unenforceability or lack of safety of our patents and proprietary rights, {our relationships} with affiliated entities, modifications and developments in know-how which can render our merchandise or applied sciences out of date, and different components. For a additional dialogue of these dangers, please discuss with the danger administration sections in Genmab’s most up-to-date monetary stories, which can be found on www.genmab.com and the danger components included in Genmab’s most up-to-date Annual Report on Form 20-F and different filings with the U.S. Securities and Exchange Commission (SEC), which can be found at www.sec.gov. Genmab doesn’t undertake any obligation to replace or revise ahead trying statements in this Company Announcement nor to substantiate such statements to mirror subsequent occasions or circumstances after the date made or in relation to precise outcomes, except required by legislation.

Genmab A/S and/or its subsidiaries personal the next logos: Genmab®; the Y-shaped Genmab emblem®; Genmab in mixture with the Y-shaped Genmab emblem®; HuMax®; DuoBody®; DuoBody in mixture with the DuoBody emblem®; HexaBody®; HexaBody in mixture with the HexaBody emblem®; DuoHexaBody® and HexElect®.

Company Announcement no. 51
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

See also  Cross Medical Group Welcomes a Plastic Surgeon

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

  • 270922_CA51_Warrant Exercise





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here